First Week of MRUS February 2026 Options Trading

A sell-to-open put trade for Merus NV (MRUS) at the $95 strike with a $6.00 bid implies an effective share cost basis of $89.00 versus the current price of $96.95, representing a ~2% out-of-the-money position. Current analytics put the probability of the contract expiring worthless at 59%; if it does, the premium yields 6.32% on cash committed (38.42% annualized). Implied volatility for the put is 61%, matching the trailing 12-month volatility, making this a volatility-neutral, income-oriented alternative to outright share purchase.

Analysis

Market structure: The immediate beneficiaries are option premium sellers and market makers capturing the 6.0 bid on the MRUS $95 put (cash at risk $9,500 per contract) while downside protection buyers pay for optionality. Because IV (61%) equals realized vol (61%), market makers are not demanding a volatility premium — this signals balanced two‑way flow rather than one‑sided hedging that would skew pricing. If many retail/professional sellers harvest YieldBoost (6.32% per contract, 38.4% annualized), the marginal supply of stock to the market rises only on assignment events, so share pressure is episodic not continuous.

Risk assessment: Tail risks are predominantly binary clinical/regulatory outcomes (probability-weighted move ±30–70% on readouts) and fast IV spikes (>80%) that would make short puts rapidly loss-making; operational counterparty risk is minimal but margin/early assignment risk is real around catalysts. Time horizon matters: immediate (days)—monitor IV and delta; short (weeks–months)—likelihood of assignment before 30–90 day clinical or corporate events; long (quarters+)—fundamental outlook for MRUS’s pipeline and cash runway. Hidden dependencies include concentrated option-seller positioning (crowded short-put book) and repo/liquidity squeeze if a sudden sell-off forces deleveraging.

Trade implications: For cash-efficient exposure, sell-to-open MRUS $95 puts 30–45D for ~6.00 collecting $600 per contract (cash at risk $9,500; effective basis $89 if assigned) but size to 0.5–2.0% of portfolio capital per contract to limit event risk. Prefer defined-risk alternatives: 30–60D put credit spread (sell 95 / buy 85) to cap max loss (~$900 per contract if net credit ≈$3–$4) and reduce margin; if expecting a binary catalyst, buy a call or straddle 7–14 days before event to capture direction. Rotate defensive: trim biotech beta by 1–3% into premium income and shift proceeds to large-cap pharma (PFE, MRK) or healthcare staples for lower tail volatility.

Contrarian angles: Consensus implicitly treats MRUS downside as limited (59% chance put expires worthless) but that understates asymmetric biotech tails — a single negative readout can blow past implied probabilities. The parity of IV and realized vol suggests options are fairly priced; therefore naked short-put upside (38% annualized yield headline) is likely overstated once assignment and drawdown risk are included. Historical parallels (small biotech with matched IV) show selling premium works until a clinical failure concentrates losses; the simple YieldBoost math masks concentration and timing risk.

Key Decisions for Investors

• Sell-to-open MRUS $95 puts (30–45D) sized so cash at risk = 0.5–2.0% of portfolio per contract (e.g., $9,500 per contract) to collect ~ $600 premium; plan to accept assignment (effective basis $89) or close if IV >80% or MRUS drops >8% intraday.
• Use a defined-risk put credit spread instead of naked puts: sell MRUS 95 / buy 85 (30–60D) targeting a net credit ≈ $3.00–$4.00 to limit max loss to ~ $900 per contract; deploy this as primary short-premium strategy until next biotech catalyst within 60–90 days.
• If a material clinical/regulatory readout is scheduled within 30–90 days, shift from premium selling to directional trades: buy MRUS calls 7–14 days before the event (delta 0.30–0.40) or purchase a 0.5–1.0% portfolio long position in stock only if implied move priced by IV <30% (opportunity threshold).
• Reduce broad biotech/IBB beta by 1–3% and reallocate proceeds to large-cap pharma (e.g., PFE, MRK) or healthcare staples for lower event risk; this hedges sector tail risk while harvesting MRUS option premium.
• Set hard exit triggers: close option exposure if IV spikes >80% (reprice >+30% vs today) or stock gap down >12% on headline — these thresholds protect against rapid gap-to-zero clinical outcomes and concentrated assignment pressure.